Kyowa Kirin gets extended EC approval for CRYSVITA in X-linked hypophosphataemia

Kyowa Kirin has secured extended approval for CRYSVITA (burosumab) from the European Commission (EC) in X-linked hypophosphataemia (XLH), to cover the treatment of older adolescents ... Read More